Hemoglobinuria

Data confirm the safety and efficacy of ravulizumab among patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab, according to results of the REACTION study presented at ASH Annual Meeting and Exposition.

Crovalimab provided disease control and proved noninferior to a current standard-of-care treatment for certain patients with paroxysmal nocturnal hemoglobinuria, according to the agent’s manufacturer.

The FDA granted priority review to pegcetacoplan for treatment of paroxysmal nocturnal hemoglobinuria, according to the agent’s manufacturer.